The story of Sildenafil presents a nuanced case for investors in the drug sector. While initially a phenomenal success, generating huge profits, the patent lapse and the subsequent arrival of cheaper versions have drastically changed income. This presents questions about the future profitability of analogous drug innovations and suggests that simpl